Granulocyte-Macrophage Colony-Stimulating Factor
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01555580 | Apr 2012 → Dec 2013 | generalized myasthenia gravis | Muscular Dystrophy Association | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03306589 | Aug 2017 → Jan 2018 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02429440 | May 2005 → Oct 2017 | renal cell carcinoma | University Hospital Tuebingen | Unknown | No outcome recorded |
| Phase 1/2 | NCT00458536 | Oct 2004 → Dec 2014 | kidney cancer | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT05817214 | Feb 2023 → Nov 2025 overdue | cervical cancer | Zhongnan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05754684 | Jan 2022 → Dec 2025 overdue | neuroblastoma | Hong Kong Children's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03046758 | Feb → Dec 2017 | appendicitis | Herlev Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02663440 | Jan 2016 → Dec 2017 | glioblastoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02332473 | Jun 2014 → Feb 2016 | chronic hepatitis B virus infection | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01363206 | May 2011 → May 2014 | metastatic melanoma | Lynn E. Spitler, MD | Completed | No outcome recorded |
| Phase 2 | NCT00004141 | Aug 1998 → Jan 2003 | cutaneous melanoma | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00001237 | Mar 1989 → Apr 2000 | Burkitt lymphoma, diffuse large B-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02327416 | Oct 2014 → Dec 2018 | chronic hepatitis B virus infection | Tongji Hospital | Unknown | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT03332329 | Dec 2015 → Dec 2018 | chronic hepatitis B virus infection | Qin Ning | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03164889 | Jan 2017 → Jan 2018 | chronic hepatitis B virus infection | Beijing 302 Hospital | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01408901 | Sep 2011 → Aug 2017 | peripheral arterial disease | Northwestern University | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 0 | NCT07077616 Background | Jul 2025 → Dec 2027 expected | glioma | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04144023 Background | Jun 2019 → Dec 2027 expected | ductal breast carcinoma in situ | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT02933944 Background | Sep 2016 → Feb 2019 | rectal cancer | Targovax ASA | Terminated | No outcome recorded |
| Phase 1/2 | NCT01592045 Background | Aug 2012 → Jun 2014 | neuroblastoma | United Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT00429416 Background | Mar 2004 → Dec 2008 | hematopoietic and lymphoid cell neoplasm | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT06047860 Background | Jun 2023 → Dec 2024 | refractory malignant neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT00969722 Background | Aug 2009 → Aug 2010 | neuroblastoma | United Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00001239 Background | Jul 1989 → Jan 2001 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Targovax Oy | Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement circio.com ↗ |
| 2019-07-03 | GlaxoSmithKline | GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA) gsk.com ↗ |
| 2018-10-21 | GlaxoSmithKline | GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis gsk.com ↗ |
| 2016-04-18 | GlaxoSmithKline | GSK announces start of a phase II study to evaluate an anti GM-CSF antibody for inflammatory hand osteoarthritis gsk.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Granulocyte-macrophage colony stimulating factor | “The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as...” NCT02933944 ↗23“We aimed to investigate the safety of intraperitoneal administration of the combination of fosfomycin, metronidazole, and recombinant human granulocyte-macrophage...” PMID 31040341 ↗ Apr 2019 “TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)” NCT07077616 ↗ “using granulocyte-macrophage colony-stimulating factor (GM-CSF) to ameliorate chemotherapy-induced toxicity.” NCT00001239 ↗ |
| Known as | GM-CSF | “The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as...” NCT02933944 ↗9“The purpose of this study was to evaluate the feasibility of hypofractionated intensity-modulated radiation therapy (IMRT), temozolomide and granulocyte-macrophage...” PMID 40090128 ↗ Mar 2025 “TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)” NCT07077616 ↗ “We plan to determine whether using granulocyte-macrophage colony stimulating factor (GM-CSF) in this group would increase dose-intensity and ameliorate myelotoxicity.” NCT00001237 ↗ “using granulocyte-macrophage colony-stimulating factor (GM-CSF) to ameliorate chemotherapy-induced toxicity.” NCT00001239 ↗ “a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)” NCT00458536 ↗ “Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)” NCT00969722 ↗ “Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)” NCT01592045 ↗ “Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)” NCT01555580 ↗ “Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)” NCT01363206 ↗ |
| Known as | rhGM-CSF | “We aimed to investigate the safety of intraperitoneal administration of the combination of fosfomycin, metronidazole, and recombinant human granulocyte-macrophage...” PMID 31040341 ↗ Apr 2019 |
| Modality | Protein / enzyme biologic | “Biological: Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)” NCT00969722 ↗ |
| Route | Subcutaneous | “Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)” NCT00969722 ↗ |